Biohaven Pharmaceuticals, a clinical stage biotech developing treatments for neurological diseases and rare disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The New Haven, CT-based company was founded in 2013 and it plans to list on the NYSE under the symbol BHVN. Morgan Stanley, Piper Jaffray and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
